A few baseline characteristics can predict the need for recurrent endoscopic sinus surgery among patients with CRSwNP.

If approved, depemokimab would be the first ultra-long-acting biologic with a six-month dosing interval for the treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal ...

LONDON - GSK plc (LSE/NYSE: GSK) has announced the acceptance of regulatory filings in China and Japan for depemokimab, a new biologic treatment for asthma with type 2 inflammation and chronic ...

Kaivan Khavandi, SVP at GSK, stated, "Simultaneous regulatory submissions for two indications highlight our confidence in depemokimab to help reduce the burden of both asthma and CRSwNP for ...

Similarly, the ANCHOR trials showed that depemokimab effectively reduced nasal polyp size and obstruction in CRSwNP patients compared to placebo. Depemokimab, a monoclonal antibody targeting ...

If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing Submissions based on data from positive SWIFT and ANCHOR trials SWIFT-1 and -2 showed depemokimab reduced ...

Recent studies have bolstered the long-held idea that recurring dreams are often — but not always — bad ones. In a 2022 survey by Michael Schredl, head of the sleep laboratory at the Central ...

Abstract: Chronic rhinosinusitis with nasal polyps (CRSwNP), as one of the most common chronic nasal inflammations, has been a major research focus in the field of rhinology due to its complex and ...

But the rise in recurring claims suggests more unemployed people are having a tougher time finding a new job. Weekly numbers tend to be volatile, however, particularly at this time of the year.